T. Rowe Price Investment Management Inc. Has $1.60 Billion Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

T. Rowe Price Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 86.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,083,900 shares of the medical research company's stock after buying an additional 1,433,444 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.0% of T. Rowe Price Investment Management Inc.'s portfolio, making the stock its 16th biggest holding. T. Rowe Price Investment Management Inc. owned approximately 0.81% of Thermo Fisher Scientific worth $1,604,338,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Barrett & Company Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth $28,000. Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. Raymond James restated an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday. StockNews.com downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday. Finally, The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday. Five analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $616.64.

Thermo Fisher Scientific Price Performance

TMO stock traded down $2.64 during trading hours on Friday, hitting $424.02. 2,698,284 shares of the stock traded hands, compared to its average volume of 1,742,310. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a 50-day simple moving average of $487.28 and a 200 day simple moving average of $527.66. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The company has a market cap of $160.06 billion, a P/E ratio of 25.65, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.